Registry Study on Rare Cancers in Korea (rarecancer)

April 27, 2026 updated by: Hyo Song Kim, Yonsei University
This study aims to determine the participation rate of patients with registered rare cancers in clinical research.

Study Overview

Status

Recruiting

Conditions

Detailed Description

Data collection includes:

  • Clinical characteristics (diagnosis, treatment information, primary/metastatic sites, staging, gender/age)
  • Survival information (diagnosis date, recurrence date, death date, disease progression)
  • Pathological information (diagnosis, genomic information)

Study Type

Observational

Enrollment (Estimated)

500

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • South Korea
      • Seoul, South Korea, 03722
        • Recruiting
        • Severance Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Data collection includes:

  • Clinical characteristics (diagnosis, treatment information, primary/metastatic sites, staging, gender/age)
  • Survival information (diagnosis date, recurrence date, death date, disease progression)
  • Pathological information (diagnosis, genomic information)

Description

Inclusion Criteria:

  • Adults aged ≥19 years
  • Confirmed rare cancer
  • Life expectancy ≥3 months

Exclusion Criteria:

-Serious or unstable medical/psychiatric conditions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Establish a registry
Time Frame: 1 year
Establish a registry of rare cancer patients visiting the institution
1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Clinical trial registration rate (%)
Time Frame: 1 year
Clinical trial registration rate (%)
1 year

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Yonsei University

Investigators

  • Principal Investigator: Hyo Song Kim, MD, Ph.D, Yonsei Cencer center

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 18, 2024

Primary Completion (Estimated)

December 1, 2027

Study Completion (Estimated)

December 1, 2027

Study Registration Dates

First Submitted

December 9, 2024

First Submitted That Met QC Criteria

December 17, 2024

First Posted (Actual)

December 24, 2024

Study Record Updates

Last Update Posted (Actual)

April 30, 2026

Last Update Submitted That Met QC Criteria

April 27, 2026

Last Verified

April 1, 2026

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 4-2024-1207 (Other Identifier: Severance Hospital, IRB)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rare Cancer

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Luxembourg

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe